OS model
| Variable . | Univariable . | Multivariable . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Leukocyte count >25 × 109/L | 1.62 (1.10-2.41) | .015 | 1.57 (1.16-2.41) | .007 |
| Platelet count <150 × 109/L | 1.89 (1.17-3.05) | .009 | 1.67 (1.16-2.40) | .006 |
| Peripheral blasts >1% | 1.03 (0.63-1.66) | .918 | ||
| Peripheral blasts (continuous) | 1.02 (0.93-1.11) | .696 | ||
| Hemoglobin <10 g/dL | 1.13 (0.70-1.84) | .617 | ||
| KPS <90% | 1.47 (1.05-2.06) | .026 | 1.50 (1.06-2.13) | .021 |
| Constitutional symptoms | 1.35 (0.95-1.92) | .092 | ||
| Transfusion dependence | 1.15 (0.81-1.64) | .423 | ||
| BM fibrosis grade >1 | 1.00 (0.66-1.53) | .999 | ||
| Driver mutation | ||||
| CALR type 1 | Reference | |||
| CALR type 2 | 1.05 (0.38-2.92) | .929 | ||
| MPL | 0.52 (0.07-4.17) | .540 | ||
| JAK2 | 2.67 (1.26-5.60) | .010 | ||
| Triple negative | 3.02 (1.19-7.67) | .020 | ||
| CALR or MPL | ||||
| Present | Reference | |||
| Absent | 2.97 (1.48-6.01) | .002 | 2.40 (1.30-4.71) | .012 |
| Age ≥57 y | 2.69 (1.59-4.56) | <.001 | 1.65 (1.15-2.36) | .006 |
| HLA-mismatched unrelated | 1.99 (1.40-2.82) | <.001 | 2.08 (1.45-2.97) | <.001 |
| HLA-match | ||||
| Matched related | Reference | |||
| Matched unrelated | 1.24 (0.75-1.93) | .303 | ||
| Mismatched related | 1.08 (0.15-7.91) | .943 | ||
| Mismatched unrelated | 2.41 (1.51-3.84) | <.001 | ||
| ASXL1 | 1.50 (1.13-2.25) | .018 | 1.42 (1.01-2.01) | .041 |
| U2AF1* | 1.48 (0.70-3.07) | .309 | ||
| DNMT3A† | 1.58 (0.90-2.61) | .100 | ||
| TP53‡ | 1.02 (0.14-7.35) | .985 | ||
| Number of mutations >3 | 1.52 (0.92-2.57) | .098 | ||
| High molecular risk¶ | 1.49 (0.89-2.48) | .129 | ||
| Cytogenetic risk (MIPSS70-plus version 2.0) | ||||
| Favorable karyotype | Reference | |||
| Unfavorable karyotype | 1.69 (0.86-3.32) | .126 | ||
| Very high risk karyotype | 0.68 (0.21-2.22) | .526 | ||
| Unfavorable karyotype (DIPSS-plus) | 1.54 (0.79-2.41) | .451 | ||
| CMV serostatus patient/donor | ||||
| −/− | Reference | |||
| −/+ | 0.85 (0.44-1.63) | .616 | ||
| +/− | 1.63 (1.02-2.67) | .045 | ||
| +/+ | 1.09 (0.72-1.66) | .676 | ||
| Time to transplant | 0.99 (0.99-1.00) | .553 | ||
| Ruxolitinib before transplant§ | 0.67 (0.35-1.29) | .228 | ||
| Splenectomy before transplant | 0.93 (0.57-1.53) | .772 | ||
| Variable . | Univariable . | Multivariable . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Leukocyte count >25 × 109/L | 1.62 (1.10-2.41) | .015 | 1.57 (1.16-2.41) | .007 |
| Platelet count <150 × 109/L | 1.89 (1.17-3.05) | .009 | 1.67 (1.16-2.40) | .006 |
| Peripheral blasts >1% | 1.03 (0.63-1.66) | .918 | ||
| Peripheral blasts (continuous) | 1.02 (0.93-1.11) | .696 | ||
| Hemoglobin <10 g/dL | 1.13 (0.70-1.84) | .617 | ||
| KPS <90% | 1.47 (1.05-2.06) | .026 | 1.50 (1.06-2.13) | .021 |
| Constitutional symptoms | 1.35 (0.95-1.92) | .092 | ||
| Transfusion dependence | 1.15 (0.81-1.64) | .423 | ||
| BM fibrosis grade >1 | 1.00 (0.66-1.53) | .999 | ||
| Driver mutation | ||||
| CALR type 1 | Reference | |||
| CALR type 2 | 1.05 (0.38-2.92) | .929 | ||
| MPL | 0.52 (0.07-4.17) | .540 | ||
| JAK2 | 2.67 (1.26-5.60) | .010 | ||
| Triple negative | 3.02 (1.19-7.67) | .020 | ||
| CALR or MPL | ||||
| Present | Reference | |||
| Absent | 2.97 (1.48-6.01) | .002 | 2.40 (1.30-4.71) | .012 |
| Age ≥57 y | 2.69 (1.59-4.56) | <.001 | 1.65 (1.15-2.36) | .006 |
| HLA-mismatched unrelated | 1.99 (1.40-2.82) | <.001 | 2.08 (1.45-2.97) | <.001 |
| HLA-match | ||||
| Matched related | Reference | |||
| Matched unrelated | 1.24 (0.75-1.93) | .303 | ||
| Mismatched related | 1.08 (0.15-7.91) | .943 | ||
| Mismatched unrelated | 2.41 (1.51-3.84) | <.001 | ||
| ASXL1 | 1.50 (1.13-2.25) | .018 | 1.42 (1.01-2.01) | .041 |
| U2AF1* | 1.48 (0.70-3.07) | .309 | ||
| DNMT3A† | 1.58 (0.90-2.61) | .100 | ||
| TP53‡ | 1.02 (0.14-7.35) | .985 | ||
| Number of mutations >3 | 1.52 (0.92-2.57) | .098 | ||
| High molecular risk¶ | 1.49 (0.89-2.48) | .129 | ||
| Cytogenetic risk (MIPSS70-plus version 2.0) | ||||
| Favorable karyotype | Reference | |||
| Unfavorable karyotype | 1.69 (0.86-3.32) | .126 | ||
| Very high risk karyotype | 0.68 (0.21-2.22) | .526 | ||
| Unfavorable karyotype (DIPSS-plus) | 1.54 (0.79-2.41) | .451 | ||
| CMV serostatus patient/donor | ||||
| −/− | Reference | |||
| −/+ | 0.85 (0.44-1.63) | .616 | ||
| +/− | 1.63 (1.02-2.67) | .045 | ||
| +/+ | 1.09 (0.72-1.66) | .676 | ||
| Time to transplant | 0.99 (0.99-1.00) | .553 | ||
| Ruxolitinib before transplant§ | 0.67 (0.35-1.29) | .228 | ||
| Splenectomy before transplant | 0.93 (0.57-1.53) | .772 | ||
Akaike information criterion, 688.629; C-index original, 0.723; bootstrap C-index: 0.712.
MIPSS, mutation-enhanced International Prognostic Scoring System.
n = 17 with U2AF1.
n = 11 with DNMT3A.
n = 3 with TP53.
High-molecular-risk category indicates the presence of a mutation in any of the following genes in a patient: ASXL1, EZH2, SRSF2, or IDH1/2; mutation-specific HRs were 1.50 (P = .018) for ASXL1, 0.69 (P = .522) for EZH2, 0.85 (P = .734) for SRSF2, and 0.91 (P = .855) for IDH1/2.
Median follow-up in ruxolitinib and nonruxolitinib cohorts were 2.5 and 5.8 years; HR is shown for 3-year survival.